You are on page 1of 1

1743

JACC March 20, 2018


Volume 71, Issue 11

Prevention
SGLT2 INHIBITORS REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS IN TYPE 2 DIABETIC
PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Moderated Poster Contributions
Prevention Moderated Poster Theater, Poster Hall, Hall A/B
Sunday, March 11, 2018, 4:00 p.m.-4:10 p.m.

Session Title: Managing and Understanding T2DM: The New Imperative For CV Clinicians
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1272M-05

Authors: Shamna Haris, Sukhchain Singh, Sana Chaudhary, Mahwash Siddiqui, Onyambu Steve Biko, Sarabjeet Singh, Haris Hamsakutty,
Sandeep Khosla, Rohit Arora, Rosalind Franklin University of Medicine and Sciences, Chicago, IL, USA, Mount Sinai Hospital, Chicago, IL,
USA
Background: The association between sodium-glucose co transporter 2 (SGLT2) inhibitors and Major Adverse Cardiovascular Events in
individuals with type 2 diabetes remain uncertain. This meta-analysis aimed to evaluate the cardiovascular outcomes of FDA approved
SGLT2 inhibitors for treatment of diabetes mellitus.
Methods: We searched electronic databases from inception through September 2017 for randomized controlled trials of at least 24 weeks
follow up, comparing FDA approved SGLT-2 inhibitors (empagliflozin, cangliflozin or dapagliflozin) to placebo or other active anti diabetic
treatments. The effect estimates were pooled using Der-Simonian and Laird random-effects meta analysis models.
Results: Forty five trials comprising 43, 123 patients were included in this study. Mean follow up was 60 weeks. Mean age of patients was
59.7 years and mean BMI was 30.6. The SGLT2 inhibitors compared with placebo or other antidiabetic treatments were associated with
13 % relative risk reduction of Major Adverse Cardiovascular Events (Risk Ratio [RR] 0.87; 95% CI 0.81 to 0.94). There was no significant
statistical heterogeneity among the contributing trials.
Conclusion: This meta analysis showed that the three FDA approved SGLT2 inhibitors are associated with lower risk of Major Adverse
Cardiovascular Events when used to treat patients with type 2 diabetes mellitus. Prospective trials of these agents in CV disease may be a
new therapeutic target for CV risk reduction.